New Therapeutic Antibody Discovery Collaboration
Proprietary antibody libraries to help discover therapeutic antibodies against multiple targets
Search
Partnership with IBM to accelerate new antibody therapies
Boehringer Ingelheim collaborates with IBM to advance generative AI and foundation models for therapeutic antibody development
Agreement-to-acquire-NBE-Therapeutics
Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Collaboration-with-OxfordBioTherapeutics
Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Partnership-with-clicktherapeutics
Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
Monoclonal antibodies Boehringer Ingelheim and Invetx
Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics
Partnering pet therapeutics
Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
Digital Therapeutic
Digital Therapeutic
TREM-1 Antibody
TREM-1 Antibody
PD-1 antibody
PD-1 antibody
IL11 antibody
IL11 antibody
Monoclonal Antibody Production | Bioxcellence | Boehringer Ingelheim
Explore our advanced capabilities in antibody production, and learn about the unique features of monoclonal & polyclonal antibodies.
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Therapeutics
Therapeutics
FDA Grants Breakthrough Status to Schizophrenia Treatment
Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic
IL-11 inhibitor antibody clinical development launched
Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
Ezabenlimab
Ezabenlimab, PD-1 antibody
Spesolimab (BI 655130)
Spesolimab (BI 655130): IL36R antibody
Boehringer Ingelheim announces collaboration with MabGenesis
Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
CT-155
Digital therapeutic
License deal with A*STAR to develop cancer antibodies
License deal with A*STAR to develop cancer antibodies
Spesolimab (BI 655130)
Spesolimab (BI 655130): IL36R antibody
Spesolimab (BI 655130)
Spesolimab (BI 655130): IL36R antibody Netherton Syndrome
The digital therapeutic solution halving hospitalization rates
Around 750,000 people live with chronic heart failure in Canada. The Medly program empowers patients with heart failure to manage their condition